Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares stood at 4.37 million during the last session, with the company’s beta value hitting 1.05. At the close of trading, the stock’s price was $0.71, to imply a decrease of -1.95% or -$0.02 in intraday trading. The LXRX share’s 52-week high remains $3.73, putting it -425.35% down since that peak but still an impressive 12.68% since price per share fell to its 52-week low of $0.62. The company has a valuation of $257.89M, with an average of 5.55 million shares in intraday trading volume over the past 10 days and average of 4.82 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Lexicon Pharmaceuticals Inc (LXRX), translating to a mean rating of 1.67. Of 3 analyst(s) looking at the stock, 0 analyst(s) give LXRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.12.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
After registering a -1.95% downside in the last session, Lexicon Pharmaceuticals Inc (LXRX) has traded red over the past five days. The 5-day price performance for the stock is -17.00%, and -11.96% over 30 days. With these gigs, the year-to-date price performance is -3.40%. Short interest in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw shorts transact 33.5 million shares and set a 6.41 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, LXRX has been trading -745.07% off suggested target high and -745.07% from its likely low.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Looking at statistics comparing Lexicon Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Lexicon Pharmaceuticals Inc (LXRX) shares are -68.01% down over the last 6 months, with its year-to-date growth rate lower than industry average at 16.46% against 16.70%. The rating firms project that company’s revenue will grow 824.52% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 6.48M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 3.05M.Earnings reports from the last fiscal year show that sales brought in 702k and 1.13M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 822.99% before jumping 169.94% in the following quarter.
LXRX Dividends
Lexicon Pharmaceuticals Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Lexicon Pharmaceuticals Inc insiders hold 1.15% of total outstanding shares, with institutional holders owning 81.95% of the shares at 82.90% float percentage. In total, 81.95% institutions holds shares in the company, led by ARTAL GROUP S.A.. As of 2024-06-30, the company held over 175.1 million shares (or 71.3555% of shares), all amounting to roughly $294.17 million.
The next major institution holding the largest number of shares is FMR LLC with 38.69 million shares, or about 15.7656% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $64.99 million.
We also have Fidelity Growth Company Fund and Fidelity Growth Company K6 Fund as the top two Mutual Funds with the largest holdings of the Lexicon Pharmaceuticals Inc (LXRX) shares. Going by data provided on Nov 30, 2024 , Fidelity Growth Company Fund holds roughly 17.24 shares. This is just over 4.77% of the total shares, with a market valuation of $12.3 million. Data from the same date shows that the other fund manager holds a little less at 5.62, or 1.56% of the shares, all valued at about 4.01 million.
